Cagrilintide
Same price per vial — no bulk discount, just add more to one order.
20% off included — code WELCOME20 is reflected in this price and applied automatically at checkout.
For laboratory research use only · Not for human consumption · Read handling terms →
Lab-grade material. Proof in every order.
Third-party HPLC, mass-spec, and endotoxin testing on every batch — with the Certificate of Analysis included, not on request.
Overview+
Cagrilintide is a long-acting amylin analog studied for its role in metabolic and appetite-regulation signaling. It is of interest in research into energy balance and glucose homeostasis, and it is often examined for how it complements other metabolic signaling pathways.
History+
Developed in the 2010s as the first long-acting amylin analog, cagrilintide was engineered for a once-weekly profile and studied in combination with GLP-1 receptor agonists for additive effects on appetite and weight-related endpoints. That combination work is a large part of why it became a reference compound in metabolic research.
Structure & specifications+
Research findings+
Cagrilintide has been examined in metabolic and central-nervous-system models for amylin- and calcitonin-receptor agonism, satiety signaling in the dorsal vagal complex and lateral parabrachial nucleus, and weight-related pathways. Because amylin signaling acts through a different route than the incretin pathways, cagrilintide is frequently studied as a complement to GLP-1 agonists rather than a substitute. As the first long-acting analog in its class, it serves as a reference tool for research on satiety and central appetite regulation.
- →Metabolic: Satiety, energy balance
- →Endocrine: Amylin/calcitonin-receptor signaling
- →Neurological: Central appetite-regulation pathways
Shipping, storage & handling+
Same-day dispatch before 2:00 PM CST, Monday through Saturday. Store lyophilized vials at −20°C, protected from light; reconstituted solutions at 2–8°C. Discreet, temperature-safe packaging. Guaranteed delivery with free reshipment.
References+
- Lau DCW. et al. (2021). Amylin-analog effects on body weight (phase 2).
- Enebo LB. et al. (2021). Co-administration of an amylin analog with a GLP-1 agonist.
- Kruse T. et al. (2021). Discovery and pharmacology of a long-acting amylin analog.
What’s actually in your vial?
Most researchers don’t ask. The ones who do, switch.
Text us, our dedicated team is here to help.
Reach out and get a response within minutes.
